ORIC Pharmaceuticals to Present Preclinical Data on CD73 Inhibitor Program in Multiple Myeloma at the 64th American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 11/03/22
ORIC Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational UpdateGlobeNewsWire • 08/11/22
ORIC Pharmaceuticals to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 05/17/22
ORIC Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational UpdateGlobeNewsWire • 05/09/22
ORIC Pharmaceuticals Presents Promising Preclinical Data on Three Programs at the 2022 American Association for Cancer Research (AACR) Annual MeetingGlobeNewsWire • 04/12/22
ORIC Pharmaceuticals, Inc.'s (ORIC) CEO Jacob Chacko on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/22/22
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational UpdateGlobeNewsWire • 03/21/22
ORIC Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results and Operational Update Conference CallGlobeNewsWire • 03/17/22
ORIC Pharmaceuticals Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual MeetingGlobeNewsWire • 03/08/22
ORIC Pharmaceuticals to Participate in the Guggenheim 2022 Oncology ConferenceGlobeNewsWire • 02/02/22
ORIC Pharmaceuticals Announces Regulatory Clearance of Clinical Trial Application for ORIC-114 in Advanced Solid Tumors with EGFR or HER2 Exon 20 Alterations or HER2 AmplificationsGlobeNewsWire • 01/25/22
ORIC Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/22
ORIC Pharmaceuticals Presents Data Supporting the Therapeutic Potential of ORIC-533 in Multiple Myeloma at the American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 12/13/21
ORIC Pharmaceuticals to Host ASH Conference Call with Key Opinion Leader to Discuss Potential of ORIC-533 in Multiple MyelomaGlobeNewsWire • 12/09/21
ORIC Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational UpdateGlobeNewsWire • 11/08/21
ORIC Pharmaceuticals to Present Update on CD73 Inhibitor Program in Multiple Myeloma at the American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 11/04/21
ORIC Pharma's Shares Plunge As Initial ORIC-101 Data In Prostate Cancer Fails To Impress InvestorsBenzinga • 10/07/21
ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTCGlobeNewsWire • 10/07/21